Heavy volume on Tuesday 3,348k vs. avg. 1,201k, but after hours was 898k alone with 3 trades over 100k, largest 194,527 shares. Most over $112 in the first 30 minutes of trading. MDVN doesn't usually trade much in the after hours sessions. Right near after hours close some much smaller trades at 110ish, maybe a little price manipulation. And Barron's is showing an uptick/downtick trade ratio of 5.36 (1 being neutral), that's the highest I've ever seen it on Barron's, very bullish number for Tuesday's session with $140.52 million net money inflow for the day. That tells me this stock is under heavy accumulation.
You've been wolverine-ing this stock since Oct. '13. Back when you loved DNDN because it was "natural". In the meantime MDVN is up 111% and DNDN is down 95%. What are your other picks?
Generic Zytiga is already available in India and online but it will be sold in the U.S. in 2015. Zytiga, taking with prednisone lowers PSA from 150 to just 5. It is already 30% less than Xtandi, but the generic will be 90% less in costs so it will take almost all of the market.
The conference was in London so it was out before the market on Thursday. The rise on Thursday when most of the biotechs were down was the tell.
I assume the analysts didn't like what he had to say since we are down $2.50 on a very good market day.
I listened to the Jefferies Global HC Conf. from morning of 11/20 just now. Not a lot to add except that CEO David Hung seems very determined and confident that his company will be able to push Xtandi into ever earlier use in prostate treatment and greatly expand the use of Xtandi. Of course he wouldn't give out trial data (though questioned about it), but his presentation was very focused on the opportunity against both Casodex (620,000 scripts in the US alone) and Lupron (newest study just initiated). Lupron is used when there is a biochemical recurrence but isn't approved per se. On 10/31/14 Astellas said this "Phase 3 clinical trial that will evaluate the efficacy and safety of enzalutamide in patients with high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred (rising prostate-specific antigen [PSA] level) following definitive local therapy with radical prostatectomy and/or radiation therapy. Currently, there is no prescription medicine specifically approved in the United States for these patients."
Hung said that they had patients still alive from the initial 2007 study who were still on Xtandi, considering how late Xtandi was being used in treatment then that's impressive. TERRAIN data to be released in early 2015, STRIVE data a few months after that. Breast Cancer 2nd week of December.
PCYC is projected to have much more revenue in 2016, 2017, 2018. Furthermore, their drug can be applied to many more cancers alone and in combination with other drugs. Thus there are many more partnership opportunities and fat pay checks from licensing partners in PCYC. I wish there was a good resource that showed the revenue beyond 2015. I had to dig around to get the numbers for 2016-2018 for both PCYC and MDVN. I like both stocks but PCYC has more growth potential IMHO.
Is what this Riceen person wrote in Sunday's letter. How does he know what the future will bring? Anybody could guess and be 87% right.
Riceen is about 105 and still active as can be. He has thousands of followers that. Buy and sell on his command. He know's a lot about medication and gives his predictions on it's future.